Investigation into the efficiency and prognostic elements of CT-guided ¹²⁵I particle implantation for liver cancer.

IF 3.5 2区医学 Q2 ONCOLOGY

Cancer Imaging Pub Date : 2025-07-11 DOI:10.1186/s40644-025-00909-6

Yuxiao Xia, Quanyu Zhou, Xue Jiang, Wenling Tu, Qian Liu, Liangshan Li, Yuhong Shi

{"title":"Investigation into the efficiency and prognostic elements of CT-guided ¹²⁵I particle implantation for liver cancer.","authors":"Yuxiao Xia, Quanyu Zhou, Xue Jiang, Wenling Tu, Qian Liu, Liangshan Li, Yuhong Shi","doi":"10.1186/s40644-025-00909-6","DOIUrl":null,"url":null,"abstract":"Purpose: This study assessed the effectiveness and prognostic factors of CT-guided ¹²⁵I seed implantation for primary hepatocellular carcinoma (HCC).Methods: A retrospective analysis of 71 patients (57 males, 14 females, median age 64) treated at three Chinese hospitals from 2018 to 2024 was conducted. The main outcomes were local progression-free survival (LPFS) and overall survival (OS). Treatment involved a 16-slice Spiral CT and Radioactive Particle Treatment Planning System (TPS), with seeds of 18.5-29.6 MBq implanted via freehand puncture. Efficacy was evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) at three months, with follow-ups every three months for three years, then biannually until December 2024. Data analysis utilized SPSS 22.0, Kaplan-Meier, and Cox models.Results: With a median follow-up of 37 months, the complete response (CR) rate was 57.7%, partial response (PR) 31.0%, stable disease (SD) 5.6%, and progressive disease (PD) 5.6%. Local control was 94.3%. LPFS rates at 1, 3, and 5 years were 74.6%, 29.5%, and 1.4% (median LPFS 22 months), while overall survival (OS) rates were 88.7%, 47.8%, and 12.6% (median OS 35 months). CR was a key protective factor for LPFS and OS. Significant factors included the Barcelona Clinic Liver Cancer (BCLC) stage C, intrahepatic progression, and extrahepatic metastasis. Postoperative complications occurred in 35.2% of patients, with no severe cases.Conclusion: CT-guided ¹²⁵I seed implantation is effective and safe for primary HCC, with CR being crucial for survival. Large-scale studies are needed to confirm these results.","PeriodicalId":9548,"journal":{"name":"Cancer Imaging","volume":"25 1","pages":"89"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247236/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40644-025-00909-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study assessed the effectiveness and prognostic factors of CT-guided ¹²⁵I seed implantation for primary hepatocellular carcinoma (HCC).

Methods: A retrospective analysis of 71 patients (57 males, 14 females, median age 64) treated at three Chinese hospitals from 2018 to 2024 was conducted. The main outcomes were local progression-free survival (LPFS) and overall survival (OS). Treatment involved a 16-slice Spiral CT and Radioactive Particle Treatment Planning System (TPS), with seeds of 18.5-29.6 MBq implanted via freehand puncture. Efficacy was evaluated using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) at three months, with follow-ups every three months for three years, then biannually until December 2024. Data analysis utilized SPSS 22.0, Kaplan-Meier, and Cox models.

Results: With a median follow-up of 37 months, the complete response (CR) rate was 57.7%, partial response (PR) 31.0%, stable disease (SD) 5.6%, and progressive disease (PD) 5.6%. Local control was 94.3%. LPFS rates at 1, 3, and 5 years were 74.6%, 29.5%, and 1.4% (median LPFS 22 months), while overall survival (OS) rates were 88.7%, 47.8%, and 12.6% (median OS 35 months). CR was a key protective factor for LPFS and OS. Significant factors included the Barcelona Clinic Liver Cancer (BCLC) stage C, intrahepatic progression, and extrahepatic metastasis. Postoperative complications occurred in 35.2% of patients, with no severe cases.

Conclusion: CT-guided ¹²⁵I seed implantation is effective and safe for primary HCC, with CR being crucial for survival. Large-scale studies are needed to confirm these results.

查看原文本刊更多论文

ct引导下¹²- 1粒子植入治疗肝癌疗效及预后因素探讨。

目的：评价ct引导下¹²5 - 1粒子植入术治疗原发性肝癌的疗效及影响预后的因素。方法：回顾性分析2018 - 2024年在中国三家医院治疗的71例患者（男57例，女14例，中位年龄64岁）。主要结局为局部无进展生存期（LPFS）和总生存期（OS）。治疗包括16层螺旋CT和放射性粒子治疗计划系统（TPS），通过徒手穿刺植入18.5-29.6 MBq的粒子。使用修改后的实体肿瘤反应评估标准（mRECIST）在三个月时评估疗效，每三个月随访一次，持续三年，然后每两年随访一次，直到2024年12月。数据分析采用SPSS 22.0、Kaplan-Meier和Cox模型。结果：中位随访37个月，完全缓解（CR）率为57.7%，部分缓解（PR）率为31.0%，病情稳定（SD）率为5.6%，病情进展（PD）率为5.6%。局部控制率为94.3%。1年、3年和5年的LPFS率分别为74.6%、29.5%和1.4%（中位LPFS 22个月），而总生存率（OS）为88.7%、47.8%和12.6%（中位OS 35个月）。CR是LPFS和OS的关键保护因素。重要因素包括巴塞罗那临床肝癌（BCLC） C期、肝内进展和肝外转移。术后并发症发生率为35.2%，无重症病例。结论：ct引导下¹²5 - 1粒子植入术治疗原发性肝癌有效、安全，CR对生存至关重要。需要大规模的研究来证实这些结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Imaging ONCOLOGY-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Cancer Imaging is an open access, peer-reviewed journal publishing original articles, reviews and editorials written by expert international radiologists working in oncology. The journal encompasses CT, MR, PET, ultrasound, radionuclide and multimodal imaging in all kinds of malignant tumours, plus new developments, techniques and innovations. Topics of interest include: Breast Imaging Chest Complications of treatment Ear, Nose & Throat Gastrointestinal Hepatobiliary & Pancreatic Imaging biomarkers Interventional Lymphoma Measurement of tumour response Molecular functional imaging Musculoskeletal Neuro oncology Nuclear Medicine Paediatric.